Introduction
The WHO lymphoma classification lists three distinct types of anaplastic large cell lymphoma (ALCL), 1 which among other features share the presence of large atypical CD30 þ cells. 2 Anaplastic lymphoma kinase (ALK)-positive ALCL accounts for about 60% of ALCL and expresses an oncogenic ALK-fusion protein, resulting from a translocation involving most commonly the nucleophosmin (NPM) and ALK genes. 3, 4 ALK À ALCL is morphologically similar to ALK þ ALCL, but lacks ALK expression. 5 Third, a primary cutaneous ALK À ALCL (cALCL) exists. 6 ALK þ ALCL has a favourable prognosis, whereas ALK À ALCL has an unfavourable prognosis. 5 The prognosis of primary cALCL is excellent, but for diagnosis, a secondary cutaneous involvement by systemic ALCL must be excluded. 6 Little is known about the pathogenesis of ALCL, especially for the two ALK À forms. Most ALCL show clonal rearrangements of the T-cell receptor (TCR) loci supporting a T-cell derivation. 7 Yet, an aberrant T-cell immunophenotype may occur ('null-cell' phenotype), defined by the lack of several T-cell antigens. [8] [9] [10] [11] Therefore, it is still unclear whether ALCL is derived from CD4 þ or CD8 þ T cells, from natural killer T (NKT) cells orFfor the cases lacking T-cell receptor rearrangementsFnatural killer (NK) cells. Expression of cytotoxic molecules and activation markers implies a relationship with activated cytotoxic lymphocytes. 10, 11 A derivation from interfollicular CD30 þ T-cell blasts is also discussed. 12 Substantial morphological and immunophenotypical overlap exists between ALK À ALCL and some variants of classical Hodgkin lymphoma (cHL). The neoplastic Hodgkin and Reed-Sternberg (HRS) cells of cHL also express CD30, are commonly derived from germinal centre B cells, but lack expression of most B-cell markers and may express T-cell molecules. 13, 14 Besides PAX5/BSAP, which is expressed in most cHL, but not in ALCL, no phenotypic marker has been identified to unambiguously distinguish cHL, especially tumour cell-rich cases, from ALK À ALCL. 7 We compared gene expression profiles of laser-microdissected neoplastic cells of ALK þ , ALK À and cALCL with each other and with expression profiles of cHL and of flow-cytometrically isolated cells of the main subsets of normal T and NK cells to gain insight into the pathogenesis and relationship of these lymphomas.
Materials and methods

Cell lines and normal T/NK cells
The ALK þ ALCL cell lines Karpas 299, SR786 and SUDHL1 were grown in RPMI-1640 with Glutamax-1 (Invitrogen, Karlsruhe, Germany), 10% fetal calf serum and 100 U/ml penicillin/streptomycin at 37 1C in an atmosphere containing 5% CO 2 . A total of 2000 cells of each cell line were sorted by fluorescence-activated cell sorting (FACS) into Purescript lysis buffer (Gentra, Minneapolis, USA). Tonsils for the isolation of resting and activated CD4 þ and CD8 þ T cells, regulatory T cells (Treg), CD30 þ CD3 þ T cells and NK cells were obtained from 17 patients undergoing routine tonsillectomy. NKT cells were isolated from peripheral blood of five healthy donors. The number of the tonsil or blood donor from which each subset stems is indicated in the sample name by 'T' for 'tonsil' or 'B' for 'blood' plus the respective number. Mononucleated cells from tonsils and blood samples were purified by Ficoll density centrifugation (Amersham, Uppsala, Sweden). T helper and regulatory cells were isolated by magnetic cell separation (MACS), using the CD4 þ T-cell isolation kit II (Miltenyi Biotech, Bergisch Gladbach, Germany) followed by flow-
high regulatory T cells (Treg). Cytotoxic T-cell subsets were isolated using the CD8 þ T-cell isolation kit II (Miltenyi Biotech) followed by FACS sorting of (Gentra) . The following antibodies were used: CD3-PE-TexasRed (Caltag International, Hamburg, Germany), CD3-APC-Cy7, CD4-PE, CD8-PE, CD56-PE, CD30-PE, CD25-FITC, HLA-DR-FITC, Va24JaQ-PE (all BD Pharmingen Europe, Heidelberg, Germany), Vb11-FITC (Immunotech, Marseille, France). For several samples, sorting purity could be reassessed and was mostly X90%, and in some instances 495%. Cell samples were immediately cooled at 0-4 1C to avoid changes in gene expression. The Internal Review Board in Essen approved these studies.
ALCL and tumour cell-rich cHL cases
Diagnoses of ALCL were based on the WHO classification. 1 Details of the cases are provided in Table 1 . ALCL and cHL cases with intact RNA were selected for microdissection and gene expression profiling. Total RNA was isolated from frozen lymphoma sections with Trizol (Invitrogen) followed by RNeasy Mini Kit column purification (Qiagen, Hilden, Germany) and RNA integrity was assessed on a 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). The work with primary tumour material was approved by the local Ethics Committee in Frankfurt.
Staining and microdissection of lymphoma cases
For microdissection, 5-mm-thick frozen lymph node, spleen or skin biopsy sections were mounted on membrane-covered slides (PALM, Bernried, Germany) and incubated with hematoxylin containing 200 U/ml RNase inhibitor (Roche, Mannheim, Germany) for 4 min. After washing in RNAse-free water for 2 min, sections were incubated in 2% eosin for 15 
Microarray procedure and statistical analysis
After RNA isolation from microdissected or sorted cells, labelled anti-sense RNA was generated by a two-rounded in vitro transcription protocol and hybridized to Affymetrix HGU133 Plus 2.0 arrays, as detailed in Supplementary Methods and Ref 15 . The complete gene expression dataset has been deposited in the Gene Expression Omnibus under accession no. GSE14879. The statistical analysis is provided as Supplementary Methods and in Ref 15 .
Quantitative RT-PCR
The details of the quantitative RT-PCR are given in the Supplementary Methods.
Immunohistochemistry
Paraffin sections of formalin-fixed normal tonsils and lymph node biopsies from patients with systemic ALCL or skin biopsies from patients with cALCL were used for immunohistochemical stainings. The source of the antibodies used and staining details are given in Supplementary Methods.
Results
Unsupervised hierarchical clustering of ALCL and normal T and NK cells À systemic and cALCL. The latter two intermingled in one branch. Overall, the unsupervised hierarchical clustering grouped the samples according to cell types, thereby supporting the reliability of our analysis. A contribution of the isolation method to the separate clustering of normal and malignant cells cannot be excluded. However, clustering of the sorted ALK þ ALCL cell lines in the main branch of the microdissected lymphoma cells showed that the isolation method was not the main determinant of the clustering. Moreover, in a recent analysis of various human B-cell subsets using a similar approach, microdissected and FACS-isolated marginal zone B-cells clustered close to each other, further arguing that the isolation method does not have a major influence on the interpretation of the gene expression profiles (not shown).
Closest normal cellular counterpart of ALCL
In lymphoid malignancies, neoplastic cells usually retain key gene expression features of their cell of origin. 16 To delineate the normal counterpart of ALCL, we conducted multiple principal component analyses (PCAs) . On the basis of the genes differentiating T from NK cells, all ALCL types strongly resemble T cells (Figure 2a ). Considering the cytotoxic immunophenotype of ALCL, PCAs revealed that ALCL are much more similar to CD8 than to NK or NKT cells (Figure 2b and c). However, ALCL seemed equally different from CD4 and CD8 T cells and cannot be assigned to one or the other subset ( Figure 2d ). Regarding Derived from a patient who received a heart transplant 111 months before lymphoma development, EBV + by in-situ-hybridization. ALK, anaplastic lymphoma kinase; BCR, B-cell receptor; EBV, Epstein-Barr virus; EMA, epithelial membrane antigen; GZMB, granzyme B; LAT, linker for activation in T cells; PRF1, perforin1; TCR, T-cell receptor; TIA1, T-cell intracellular antigen 1; LD, lymphocyte depleted; NSII, nodular sclerosis type II; MC, mixed cellularity.
Pathogenesis of anaplastic large cell lymphomas S Eckerle et al genes distinguishing resting and activated T cells, all ALCL types show an expression profile similar to that of activated T cells (CD3A), with ALK þ ALCL showing an even stronger, 'hyperactivated' status ( Figure 2e) . However, the ALCL could not be assigned to either CD4A or CD8A cells, largely because of low expression of genes discriminating CD4A from CD8A cells by the ALCL cells (Figure 2f , not shown). Finally, in the comparison with activated CD4 þ and CD8 þ T cells and CD30 þ T cells, the expression pattern of ALK À ALCL (although with a broad variation), and in particular cALCL, resembled activated T cells more than CD30 þ T cells, whereas ALK þ ALCL could not be clearly assigned to either of these normal T-cell subtypes (this picture did not change when CD4A or CD8A were separately compared with CD30 þ T cells, not shown) (Figure 2g ).
Loss of T-cell phenotype
As PCA revealed a great relatedness of ALCL to activated T cells, a supervised analysis was conducted between each ALCL entity and CD3A cells (Supplementary Table S1 shows the top 15 upand downregulated probe sets). In addition to the various T-cell markers, which are absent in ALCL immunohistologically, 7, 8 we identified many genes with important functions in T-cells downregulated in ALCL compared with activated T cells (not shown). A PCA for B and T cells with a comprehensive list of 459 T-cell characteristic genes (Figure 3a) showed that ALCL shift away from T cells and are as different from T cells as they are from B cells (Figure 3a) , which is mainly attributable to the downregulation of T-cell genes. Our gene expression data thus reveal a general reduction of T-cell gene expression in ALCL.
NFkB activity in ALCL
Nuclear factor kappa B (NFkB) is an important transcription factor involved in T-cell proliferation and survival. Its deregulated activation is associated with oncogenesis. 17 For ALCL cell lines, a rather low NFkB activity has been described. 18, 19 We assembled a list of 115 informative NFkB target genes (see legend of Figure 3 for details) and used it for a PCA with CD3R and cHL cells, representing cells with low and high NFkB activity, respectively. All ALCLs and cell lines showed an NFkB activity significantly higher than in CD3R and CD3A cells (Figure 3b ), but not as pronounced as in cHL, with the possible exception of ALK þ ALCL. The degree of NFkB target gene expression was similar in all ALCL types, although cALCL showed wide variation. Thus, the neoplastic cells of ALCL .05 and at least 1.9-fold up-or downregulation between the different groups for PCAs (b) to (e) and threefold for PCA (a) and (g), P-value (t-test) p0.01 and FC X1.9 or pÀ1.9 for f. In f, the P-value of the t-test was applied for filtering, as only few consistent differences were detected between CD4A and CD8A, and FDR is not appropriate for statistical testing in this instance. Small squares represent individual cell samples of the respective cell type and are placed along the main principle component, which accounts for (a) 72, (b) 82, (c) 78, (d) 74, (e) 77, (f) 87 and (g) 75% of the total variance of the respective expression matrices. Box plots summarize the scores displayed by each group in this component. Statistical significance (Pp0.05) of the pairwise comparisons was tested using Wilcox rank sum test. If not otherwise indicated, the differences between all pairwise comparisons were significant (Pp0.05) (*P40.05).
showed an increased expression of a substantial fraction of known NFkB target genes. Table S2 ). Only some of them have formerly been shown to be expressed in ALK þ ALCL. 9, 22, 23 With relaxed filter criteria (FDR p0.2), a few more genes with increased expression in ALK À ALCL were retrieved (not shown), including microRNA155, CD160 and lysozyme. As expected, several genes expressed at higher level in ALK þ ALCL are induced by signalling molecules known to be activated by the ALK-fusion protein, for example the STAT3 targets CD25, SOCS3 (suppressor of cytokine signalling 3) and C/EBPD (CCAAT/enhancerbinding protein delta), the PI3K/Akt targets GAS1 (growth arrest specific 1), paraoxonase 2 and solute carrier family 2, and the Ras target transmembrane protein 158. 3 Hence, increased expression of many genes in ALK þ compared with ALK À ALCL seems to be associated with ALK activity in line with earlier studies. 3 
Genes differentially expressed between ALK
À ALCL and cALCL Primary systemic and cALCL are morphologically and immunohistochemically very similar, but differ substantially clinically. Supervised analysis of these two lymphomas and filtering with low stringency (t-test P-value p0.05, FCX3 or pÀ3) retrieved only 26 genes with consistent differential expression (Supplementary Table S3 ), all of them with higher expression in the systemic subtype. This observation supports a close biological relatedness of the tumour cells of these two ALCL entities and suggests a differential role of the tumour environment and/or post-transcriptional alterations in their pathogenesis.
Molecular signatures associated with HL and ALCL
ALK
À ALCL shares many immunohistochemical and morphological features with cHL, especially with tumour cell-rich cHL, which can pose a problem in the differential diagnosis. 7, 24 We generated gene expression profiles of isolated HRS cells from four cases of tumour cell-rich HL and compared them with the ALK À ALCL profiles. Surprisingly, a supervised analysis identified only seven consistently differentially expressed genes (t-test P-value p0.01, FCX3 or pÀ3, FDRp0.8): CCL17, CD83, RAB13, TNFAIP3, SLCO3A1, IER3, and an unknown transcript, all with higher expression in HRS cells. Likely, analysis of additional cases would yield more statistically significant genes. As we had earlier generated gene expression profiles of 12 typical cases of cHL, 15 we also performed a supervised comparison of ALK À ALCL and these 12 cHL. Only 32 genes are significantly differentially expressed (FDR p0.1, FC X2 or pÀ2), 18 of them at higher level in cHL (Supplementary  Table S4 ; Supplementary Figure S1 ).
Quantitative real-time RT-PCR and immunohistochemical validation of genes with increased or decreased expression in ALCL
To exemplarily validate the differential gene transcription detected by genechip analysis, we selected three genes, fibronectin 1, nicotinamide N-methyltransferase and insulinlike growth factor-binding protein 7, which showed a 10-98-fold higher expression in the three entities of ALCL as compared with activated T cells (Supplementary Table S1 ). Quantitative RT-PCR 43 NFkB target genes provided by www.nf-kb.org, and additional NFkB target genes described in the literature. After excluding all probe sets that were not informative because signal was below background in all samples, we obtained a list of 151 probe sets, corresponding to 115 NFkB target genes. The first main component of the PCA for CD3R (CD4R and CD8R) and cHL for these NFkB target genes comprising the main variance is shown for CD3A (CD4A and CD8A) and ALCLs. The main principle component accounts for 64% of the total variance of the expression matrix of 115 NFkB target genes. Statistical significance (Pp0.05) of the pairwise comparisons was tested using Wilcoxon rank sum test (data not shown). If not otherwise indicated, the differences between all pairwise comparisons were significant (Pp0.05) (* P40.05).
with microdissected lymphoma cells of three cases of each type of ALCL as compared with three CD4A and three CD8A samples showed a consistently 8 to 42000-fold higher expression for each of the three genes in all 9 lymphomas as compared with the normal T cells (Supplementary Table S5 ). Thus, the RT-PCR analysis validated the genechip data.
On the basis of the availability of antibodies for immunohistochemistry and at least threefold difference in average mRNA expression levels between the entities, we selected several other genes for immunohistochemical stainings from the comparisons between ALCL versus activated T cells (upregulated in ALCL: SNFT, LGALS1, EZH2; downregulated in ALCL: ETS1, ITK) and ALK þ versus ALK À ALCL (higher expression in ALK þ ALCL: SATB1; higher expression in ALK À ALCL: MEOX1). EZH2, SATB1, SNFT and LGALS1 are additionally of potential pathogenetic relevance, as discussed below. For every protein, 11-20 lymphoma cases were stained for each ALCL type. The staining pattern for normal T cells was evaluated using reactive tonsils and gave the results expected from the genechip analysis (Supplementary Table S6 ). The increased or decreased expression of these genes in ALCL was confirmed also at protein level, validating the reliability of the gene expression data (Supplementary Table S6 ; Figure 4 ).
Discussion
We provide here the first genome-wide study of gene expression for isolated neoplastic cells of ALK þ , ALK À and cALCL, and compared it with the expression pattern of the main normal T and NK cell subsets and cHL. Clustering of the distinct cell samples in subtype-specific groups in the unsupervised analysis argues that specific gene expression profiles were obtained and the detection of genes known to be expressed in ALCL from earlier work (CD30, perforin, granzyme B, cyclin D3, clusterin, CD25; not shown) is also reassuring. Moreover, the quantitative RT-PCR for three differentially expressed genes as well as the immunohistochemical studies for six additional genes, which validated the genechip results in each instance, further supported the reliability of the results. Former studies of gene expression in ALCL were restricted by the low number of transcripts analysed or by the use of cell lines or whole tissue sections. 21, [25] [26] [27] [28] [29] [30] In the latter case, contamination by nonneoplastic cells can be significant (up to and partly 460% in the study of Lamant et al.), which partly explains why the gene signatures associated to the ALK status in ALCL do not considerably overlap in our and Lamant's studies (not shown). 20 Although there will certainly be also some cellular contamination in our microdissected samples (approximately o10% as cells were selected as single cells or small groups of neoplastic cells), the similar phenotype of microdissected ALCL cells and ALCL cell lines in several important aspects like the relatedness to T, NK, resting or activated cells and NFkB target gene expression (not shown) argues against a major influence of our results by contaminating cells, as does the absence of expression of B-cell-specific genes (Supplementary Figure S2) or typical macrophage and dendritic cell genes (not shown) in the profiles of primary lymphomas. It should, however, be mentioned that overall, the three ALK þ ALCL cell lines analysed here differ very much from primary ALK þ ALCL lymphoma cells as 45400 probe sets were differentially expressed between the cell lines and the primary ALCL cells (FDR p0.05, FCX2 or pÀ2; not shown). Although some differences might be due to technical matters, this comparison shows the importance to analyse primary tumour cells, as cell lines apparently have adopted many differences on growth in culture.
The present analysis supports the view that ALCL are derived from activated T cells rather than from resting T, NK or NKT cells. This is likely partly because of the growth and proliferative activity of the lymphoma cells, but may also reflect a derivation from activated normal T cells. However, ALCL could not be clearly assigned to either CD4 þ or CD8 þ activated T cells or to the rare CD30 þ T cells. This is presumably in part caused by a downregulation of the genes specifically characterizing each of these T-cell subsets, with retention, however, of the genes identifying CD3
þ T cells (versus NK cells) and CD8 þ T cells (versus NK/NKT cells). ALCL may potentially also derive from a T-cell subset(s) that was not analysed. For example, we did not study follicular T helper cells, which seem to represent the normal counterpart of angioimmunoblastic T-cell lymphomas, 31 and we did not distinguish between naive, effector memory and central memory T cells. However, as we studied the main human T-cell subsets, and as the 'hyper-activated' signature of the ALCL cells was very prominent, we conclude that ALCL likely derive from activated T cells, but have acquired a gene expression pattern that shows a loss of the differentiationspecific programme of CD4 þ , CD8 þ or CD30 þ T cells. Importantly, as the three subsets of ALCL behaved similarly in the various comparisons to normal T and NK cells, their gene expression pattern does not support a distinct cellular origin of these lymphomas.
Earlier studies have shown that ALCL lack expression of many T-cell-specific molecules. 8 We revealed an even broader loss of T-cell-typical genes, reminiscent of the loss of B-cell genes in cHL. 14 The cause for this down-modulation remains elusive, but some T-cell transcription factors are downregulated in ALCL. For example, we validated the absence of ETS1, a transcription factor controlling the expression of several T-cell-specific genes in ALCL. [32] [33] [34] [35] GATA3, EOMES and members of the NFAT family are also downregulated at varying levels (data not shown).
It was reported that ALCL lack a strong NFkB activity and that ALCL cell lines were devoid of nuclear-binding activity of NFkB subunits p65, p50 cRel, relB and p52. 18, 19 However, ALCL cell lines display active p50 homodimers, associated with BCL-3, and a subset of NFkB target genes is activated in ALCL cell lines. 36 Our gene expression study provides evidence that numerous NFkB target genes are expressed at higher levels in primary ALCL cells than in resting or activated normal T cells. Although NFkB activity in ALCL cells is weaker than in HRS cells of cHL and affects only a subset of NFkB target genes, it seems that in comparison to normal T cells, ALCL cells show a moderate upregulation of NFkB activity that contributes to the ALCL-specific gene expression pattern and that may have a function in ALCL pathogenesis. Further studies are required to clarify the potential contribution of NFkB in this respect.
Many genes upregulated in ALCL may be pathogenetically relevant. SNFT, for example, is a basic leucine zipper transcription factor, which can interact with the Jun transcription factor and which is involved in transcriptional repression. 37 IGFBP7, which modulates the metabolic activities of insulin-like growth factor, is upregulated in several types of solid cancers and has been shown to have growth promoting effects in glioma cells. 38 The upregulated EZH2 is a polycomb-group family member and is involved in maintaining a transcriptionally repressive state of genes over continuous cell generations and in the self-renewal of hematopoietic stem cells. 39 Proliferating T cells are EZH2 positive, and downregulating EZH2 in neoplastic T cells can selectively induce apoptosis. 40, 41 Targeting EZH2 in ALCL could, therefore, be used as a novel therapeutic strategy. It remains controversial whether ALK þ and ALK À ALCL are two separate entities or merely different variants of one lymphoma. Our data support the view that ALK þ ALCL is a distinct disease entity. The number of consistently differentially expressed genes between ALK þ and ALK À ALCL was, however, not very large, and the ALCL subtypes did not show significant differences when compared with the most similar normal counterpart, in terms of NFkB activity and the partial downregulation of the T-cell phenotype. Notably, many differences seem to relate to the transcriptional activation of target genes of pathways constitutively activated by the ALK-fusion protein, in line with earlier studies (reviewed in ref. 3 ). This further supports that ALK activity itself is a main determinant for the differences between ALK þ and ALK À ALCL. Surprisingly, our analysis did not reveal genes accounting for the different aggressiveness of primary systemic ALK À and primary cALCL, but rather indicates a close relatedness in terms of gene expression. As the cases of each subset are rather heterogeneous, and as we could analyse only four cases of systemic ALK À ALCL, a larger set of cases may be required to identify more consistent differences. Our data suggest that the adverse clinical behaviour may be significantly influenced not only by tumour cell-intrinsic factors, but also by the microenvironment. This view is supported by a study showing a significantly higher number of FOXP3 þ Treg cells in primary systemic than in primary cALCL. 42 However, post-transcriptional differences in the lymphoma cells could also have considerable influence on the different behaviour of these two forms of ALCL. ALK À ALCL can show a great morphological and immunohistochemical overlap with tumour cell-rich cases of cHL, hampering differential diagnosis with consequences for the treatment. 1 The present results provide evidence that ALK À ALCL and (tumour cell-rich) cHL also resemble one another at the level of their gene expression. Given the different cellular origin of ALCL and cHL, it is striking that the downregulation of multiple markers of the respective cells of origin in these two CD30 þ lymphoid malignancies results in a related, 'hyperactivated' gene expression programme. 13 Genes showing a consistently and at least several-fold different expression in ALK À ALCL and cHL may become novel markers for differential diagnosis (Supplementary Table S4 ).
The results of this study support an activated T-cell origin of ALCL, but also revealed a generalized reduction of T-cell molecule expression. ALCL subtypes showed only minor differences among each other, especially between systemic and cALCL, suggesting that the local microenvironment might be responsible for their different clinical behaviour. Genes regulated by pathways constitutively activated by ALK contribute to the expression profile of ALK þ ALCL. Finally, our data show a great transcriptional overlap between ALK À ALCL and cHL.
